Aila Biotech is a Cambridge-based spin-out developing a new class of brain-targeted immunotherapies for neuroinflammatory disease. Our patented platform enables immune-modulating biologics to be produced locally within the CNS, overcoming the blood–brain barrier while reducing peripheral off-target toxicity.

​

Our lead programme, AILA-001, is designed for primary progressive multiple sclerosis, with potential expansion across multiple indications driven by shared neuroinflammatory pathways. Aila is currently raising a Seed round to advance AILA-001 through first-in-human-enabling development and progress additional high-value biologics within the platform.

​

Aila combines world-leading neuroimmunology with experienced clinical, clinical-trial, biotech and regulatory expertise. Our mission is to change how neuroinflammatory diseases are treated and improve outcomes for patients with serious CNS disease.